Previous close | 18.40 |
Open | 18.56 |
Bid | 18.64 x 993000 |
Ask | 18.65 x 862200 |
Day's range | 18.43 - 18.81 |
52-week range | 8.20 - 19.06 |
Volume | |
Avg. volume | 1,205,717 |
Market cap | 6.233B |
Beta (5Y monthly) | 2.43 |
PE ratio (TTM) | 932.50 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix. The target size of the Offering is US$200 million in gross proceeds. In addition, Telix expects to grant the Underwriters (as defined below) a 30-day option to purchase up to an additional 15%
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET[1] agent, TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC).
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive data from the ProstACT SELECT trial ("SELECT") of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga (gallium)-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating